Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
The trade threats could reduce exports to the United States and dampen investment in Europe, dealing a blow to growth at a ...
17hon MSN
Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Saudi-based Sudair Pharma Company is set to establish its new insulin plant in the Sudair City for Industry and Businesses.
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
MoneyShow presents top investment ideas for 2024 from leading advisors. Part 10 includes Advanced Micro Devices, Novo Nordisk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback